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Abstract
Background: The role of orexin-A in regulating metabolic homeostasis has been recognized, but its association with 
antipsychotic-induced metabolic abnormalities remains unclear. We investigated the association between orexin-A levels 
and metabolic syndrome in patients with schizophrenia treated with clozapine or less obesogenic antipsychotics compared 
with nonpsychiatric controls.
Methods: Plasma orexin-A levels and metabolic parameters were determined in 159 patients with schizophrenia: 109 taking 
clozapine; 50 taking aripiprazole, amisulpride, ziprasidone, or haloperidol; and 60 nonpsychiatric controls.
Results: Orexin-A levels were significantly higher in the group taking less obesogenic antipsychotics, followed by the clozapine 
group and the controls (F = 104.6, P < .01). Higher orexin-A levels were correlated with better metabolic profiles in the patient 
groups but not in the controls. Regression analyses revealed that the patients with higher orexin-A levels had significantly 
lower risk of metabolic syndrome (adjusted odds ratio [OR] = 0.04, 95% CI: 0.01–0.38 for the 2nd tertile; OR = 0.04, 95% CI: 0.01–
0.36 for the 3rd tertile, compared with the first tertile), after adjustment for age, sex, smoking history, types of antipsychotics 
(clozapine vs less obesogenic antipsychotics), duration of antipsychotic treatment, and disease severity.
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Conclusions: Our results revealed that the orexin-A level was upregulated in patients with schizophrenia treated with 
antipsychotics, especially for the group taking less obesogenic antipsychotics. Furthermore, higher orexin-A levels were 
independently associated with better metabolic profiles. These observations suggest that an upregulation of orexin-A has a 
protective effect against the development of metabolic abnormalities in patients with schizophrenia receiving antipsychotic 
treatment.
Keywords: orexin-A, schizophrenia, antipsychotics, metabolic syndrome, clozapine
Introduction
Although some studies have suggested that schizophrenia is an 
independent risk factor for glycemic abnormalities and insulin 
resistance (Bushe and Holt, 2004; Greenhalgh et al., 2017), studies 
have consistently shown that antipsychotic treatment is associ-
ated with increased risks of metabolic syndrome (MS), which 
comprises a cluster of risk factors, including increased blood 
pressure (BP), dyslipidemia (raised triglycerides [TG] and reduced 
high-density lipoprotein cholesterol [HDL-C]), increased fasting 
plasma glucose [FPG], and central obesity, which occur jointly to 
increase the risk of type 2 diabetes mellitus (DM) and cardiovas-
cular disease (Alberti et al., 2009). Patients with schizophrenia 
who receive antipsychotics have a 2- to 4-fold higher risk of MS 
than that of the general population (McEvoy et al., 2005; Huang 
et al., 2009). The risk of MS and related metabolic abnormalities 
in relation to antipsychotic treatment varies according to the 
type of administered medication, with clozapine and olanzap-
ine being associated with the highest risk among antipsychot-
ics (Vancampfort et al., 2015). Furthermore, the susceptibility to 
metabolic abnormalities varies among individuals (Lieberman 
et al., 2005). However, the mechanisms underlying the different 
liabilities remain unclear.
Orexins (i.e., hypocretins) are neuropeptides mainly pro-
duced by neurons located in the lateral hypothalamic area and 
have been suggested to integrate central and peripheral signals 
to regulate metabolic homeostasis (Tsuneki et  al., 2010). The 
orexin system comprises 2 neuropeptides, orexin-A and orexin-
B (products of the same prepro-orexin gene), and their receptors 
(orexin receptor types 1 and 2)  (Sakurai et al., 1998). Orexin-A 
has enhanced feeding behavior in preclinical studies (Sakurai 
et  al., 1998). Furthermore, it has been shown to be beneficial 
for metabolic functions. Exogenous orexin-A administration 
stimulates thermogenesis and energy expenditure (Messina 
et al., 2014) by increasing sympathetic nervous systemic activ-
ity (Shirasaka et al., 1999; Messina et al., 2018), particularly the 
signals to brown fat tissues (Messina et  al., 2017). Exogenous 
orexin-A administration in mice also reduces blood glucose lev-
els by increasing insulin secretion and prevents insulin resist-
ance (Park et al., 2015; Tsuneki et al., 2015). Preclinical evidence 
suggests that the neuronal activity of orexin-A, measured using 
immediate-early gene c-Fos induction, can be altered by a single 
dose of antipsychotics, with the alteration varying among antip-
sychotics with different weight gain liabilities (Fadel et al., 2002). 
Additionally, antipsychotic administration potentially modi-
fies the ability of orexin-A to regulate energy expenditure. 
Acute antipsychotics treatment in rats, namely treatment with 
haloperidol (Monda et al., 2003), clozapine (Monda et al., 2004), 
and olanzapine (Monda et  al., 2008), reduces the sympathetic 
activation induced by exogenous orexin-A administration, 
whereas quetiapine delays the sympathetic activation (Monda 
et al., 2006). This suggests that sympathetic activation induced 
by orexin-A and ensuing hyperthermic effect, which promotes 
energy expenditure, could be blocked by antipsychotic treat-
ment and thus contributes to weight gain (Monda et al., 2018). 
However, the role of orexin-A in metabolic outcomes follow-
ing long-term antipsychotic administration in human subjects 
remains unclear.
Plasma orexin-A levels linearly correlate with its levels in 
cerebrospinal fluid (CSF) in humans, suggesting that plasma 
orexin-A levels are an easily accessible and reliable index of 
central orexin activity (Strawn et  al., 2010). Clinical studies 
investigating changes in orexin-A levels following antipsychotic 
treatment in patients with schizophrenia have reported conflict-
ing findings (Dalal et al., 2003; Basoglu et al., 2010; Chien et al., 
2015). Chien et al. (2015) reported that patients receiving chronic 
antipsychotic treatment had higher orexin-A levels compared 
with controls. Only 1 study has examined the association 
between orexin-A levels and metabolic parameters in patients 
with schizophrenia (Basoglu et  al., 2010). Because the benefit 
of antipsychotic treatment in patients with schizophrenia is 
limited by the propensity of these drugs leading to metabolic 
disturbances, clarifying the pathways underlying antipsychotic-
associated metabolic dysregulation is critical for improving clin-
ical outcomes in this group.
We investigated the relationship between orexin-A levels 
and MS in patients with schizophrenia who had been chron-
ically treated with antipsychotics. Specifically, we compared 
orexin-A levels in nonpsychiatric controls and patients taking 
antipsychotics with different weight gain liabilities, namely clo-
zapine (Baptista et  al., 2008) and other less obesogenic drugs 
(namely aripiprazole, amisulpride [Vancampfort et  al., 2015], 
ziprasidone, and haloperidol [Leucht et al., 2013]). Because evi-
dence suggests a link between orexin-A and metabolic func-
tions and that orexin-A plays an adaptive role to counteract 
antipsychotic-associated metabolic disturbances, we examined 
the hypothesis that orexin-A acts as an independent risk factor 
Significance Statement
Patients with schizophrenia have a greater risk of metabolic syndrome (MS) than the general population. Orexins are neuro-
peptides that have been suggested to integrate central and peripheral signals to regulate metabolic homeostasis. We found 
orexin-A level was upregulated in antipsychotics-treated patients with schizophrenia, and those taking clozapine had lower 
orexin-A levels than less obesogenic antipsychotics. A higher orexin-A level was independently associated with better metabolic 
profiles. Orexin-A may have a protective effect against the development of MS in schizophrenia patients receiving antipsychotic 
treatment.
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for the development of MS using age, sex, smoking, types of 
antipsychotics (i.e., clozapine vs less obesogenic drugs), dur-
ation of antipsychotic treatment, and disease severity as poten-
tial confounders.
Materials and Methods
Setting
This cross-sectional study was conducted at Taipei City 
Psychiatric Center, Taipei City Hospital from July 2011 to 
December 2014 after obtaining approval from the hospi-
tal’s Institutional Review Board (IRB nos: TCHIRB-991211, 
TCHIRB-1000407, and TCHIRB-1020812).
Study Participants
Patients with schizophrenia from either the outpatient depart-
ment or inpatient wards were consecutively recruited. Their 
clinical diagnosis was verified by 2 psychiatrists with 10 or more 
years of clinical experience. The inclusion criteria were as fol-
lows: (1) a diagnosis of schizophrenia in accordance with the 
Diagnostic and Statistical Manual of Mental Disorders (Fourth 
Edition) (Text Revision) by the American Psychiatric Association, 
(2) 20 to 65 years of age, and (3) continuous use of either cloza-
pine (Baptista et al., 2008) or a less obesogenic antipsychotic (i.e., 
aripiprazole, amisulpride, ziprasidone, or haloperidol) (Leucht 
et al., 2013; Vancampfort et al., 2015) for more than 6 months. 
Because of difficulty in enrolling drug-naïve patients with 
schizophrenia, nonpsychiatric controls were enrolled from the 
physical check-up service in the hospital by applying the fol-
lowing inclusion criteria: (1) no history of a major psychiatric 
disorder (including schizophrenia, schizoaffective disorder, 
bipolar disorder, major depressive disorder, organic mental dis-
orders, and substance abuse disorders) screened using the Mini-
International Neuropsychiatric Interview (Sheehan et al., 1998) 
and (2) 20 to 65  years of age. Written informed consent was 
obtained from each participant. Data, including demographic 
and clinical information (such as diagnoses), and the duration 
and type of antipsychotics were collected from clinical inter-
views and medical records. The severity of psychotic symptoms 
of patients with schizophrenia was assessed using the Brief 
Psychiatric Rating Scale (BPRS-18) (Lee et al., 1990).
Metabolic Parameter Measurements
Anthropometrical measurements, namely height, body weight 
(BW), waist circumference (WC), and BP, were taken by trained 
nurses. Body mass index (BMI) was calculated as the patient’s BW 
(kg) divided by height (m2). Venous blood samples were collected 
in tubes containing ethylenediaminetetraacetic acid (1 mg/mL 
of blood) anticoagulant at 8:00 to 9:00 am after an overnight 
fast to analyze FPG, glycated hemoglobin (HbA1c), insulin, TG, 
and HDL-C levels by using an automatic biochemistry analyzer. 
Plasma was separated by centrifugation, and aliquots of plasma 
were immediately frozen and stored at −80°C until analysis, 
with a storage time of 10 to 15 months. Plasma orexin-A levels 
were analyzed using an extraction-free enzyme immunosorbent 
assay (EIA) (catalog no. EKE-003-30, Phoenix Pharmaceuticals, 
Belmont, CA). The intra-assay CV was <5%, and the assay kit had 
no cross-reactivity with any other substance, namely orexin-B, 
agouti-related protein, neuropeptide, alpha-MSH, or leptin. The 
minimal detectable amount of orexin-A assay was 0.17 ng/mL 
(per the manufacturer).
MS was defined using the modified criteria of the National 
Cholesterol Education Program Adult Treatment Panel III (2005) 
(Grundy et  al., 2005), which refers to at least 3 of the follow-
ing component risk factors: (1) WC >90 cm for men or >80 cm 
for women; (2) TG ≥150  mg/dL; (3) HDL-C <40  mg/dL for men 
and <50 mg/dL for women; (4) systolic BP ≥130 mm Hg or dia-
stolic BP ≥85  mmHg or current use of antihypertensive drugs; 
and (5) FPG ≥110  mg/dL or current use of antihyperglycemic 
drugs. Obesity and overweight were defined as a BMI ≥27  kg/
m2 and ≥24  kg/m2, respectively, according to the criteria of 
the Department of Health in Taiwan (Lin et al., 2003). DM was 
defined when FPG levels were ≥126 mg/dL or antidiabetic medi-
cations were prescribed. Hypertension was defined when sys-
tolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or antihypertensive 
medications were prescribed. The homeostasis model assess-
ment for insulin resistance (HOMA-IR) value was calculated as 
FPG (mg/dL) × fasting insulin (mU/L)/405.
Statistical Analyses
Descriptive statistics were used to present the demographic, 
clinical, and metabolic characteristics of the 3 comparison 
groups (patients on clozapine, patients on less obesogenic antip-
sychotics, and nonpsychiatric controls). Logarithmic transform-
ation was applied to data for which the assumption of normality 
had been violated. One-way ANOVA was then used to compare 
the continuous variables among the 3 groups with Games–
Howell methods (Games and Howell, 1976), and posthoc tests 
were applied if significance was found. Chi-square tests were 
used to compare the categorical variables. Independent t tests 
were also performed for comparing the 2 groups, when appro-
priate. Pearson’s correlation coefficient (Pearson, 1909) was used 
for examining the correlations between orexin-A and the meta-
bolic parameters, namely BW, BMI, systolic BP, diastolic BP, FPG, 
TG, HDL-C, HbA1c, insulin, and HOMA-IR. Using MS as a dichot-
omous outcome, we applied logistic regression to assess the 
association between the groups (i.e., patients taking clozapine, 
less obesogenic antipsychotics, and nonpsychiatric controls) 
(major exposure of interest) and the presence of MS (out-
come) after adjusting for possible confounders, namely age, sex 
(Huang et al., 2009), and smoking history, without/with plasma 
orexin-A levels to examine its mediating effect (model 1/model 
2). To maximize statistical power and avoid linear assumption 
of using orexin-A level as a continuous variable in the analyses, 
we categorized the orexin-A concentration into tertiles (33.3% 
percentiles) for further analysis. Two study participants with 
missing values of orexin-A concentration were not included to 
estimate the relative risk of orexin-A on MS development in fur-
ther analysis by modeling. All P values were 2-sided. P < .05 was 
considered significant. All analyses were conducted using IBM 
SPSS Statistics version 22 (IBM Corporation, Armonk, NY).
Results
Clinical Characteristics of Metabolic Profiles of the 
Participants
Overall, 219 participants were enrolled: 109 patients taking clo-
zapine, 50 taking less obesogenic antipsychotics (aripiprazole, 
19; haloperidol, 16; amisulpride, 12; and ziprasidone, 3), and 60 
nonpsychiatric controls (Figure  1). The demographic data and 
metabolic profiles of the 3 groups are shown in Table 1. Notably, 
36%, 20%, and 10% of the participants in the clozapine, less 
obesogenic antipsychotic, and nonpsychiatric control groups, 
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respectively, fulfilled the criteria for MS, revealing a significant 
difference in the rate of MS among the groups (X2 = 14.58, P < .01). 
Continuous variables with a right-skewed distribution, namely 
BW, BMI, WC, systolic BP, diastolic BP, FPG, TG, HDL-C, HbA1c, insu-
lin, plasma orexin-A levels, as well as BPRS scores, were logarith-
mically transformed before proceeding with ANOVA. The duration 
of antipsychotic treatment was significantly different between 
the less obesogenic antipsychotic (mean = 14.94  years, SD = 9.32) 
and clozapine (mean = 19.03  years, SD = 9.56) groups (t = -2.48, 
P = .01). The BPRS scores were higher in patents taking clozapine 
(mean = 26.47, SD = 5.95) than in those taking less obesogenic antip-
sychotics (mean = 24.26, SD = 5.34) (t = 2.01, P = .04). Some metabolic 
parameters, namely WC, diastolic BP, and FPG, TG, and HDL-C lev-
els, were significantly different among the 3 groups (Table 1).
Comparisons of Plasma Orexin-A Levels in Groups
Figure  2 shows that the orexin-A levels differed across the 3 
groups (P < .01). Posthoc comparisons using the Games–Howell 
test (Figure 2) also revealed significance for each pair of compar-
isons for orexin-A levels (all values  P < .01), with the highest lev-
els in the less obesogenic antipsychotic group (mean = 1.89 ng/
mL, SD = 0.50), followed by the clozapine (mean = 1.54  ng/mL, 
SD = 0.60) and nonpsychiatric control (0.60  ng/mL, SD = 0.17) 
groups. To estimate the effect of antipsychotic treatment on 
orexin-A levels, we conducted a multiple linear regression ana-
lysis and found that the antipsychotic treatment group was sig-
nificantly associated with the orexin-A levels, after adjustment 
for age and sex (adjusted B-value = 1.26, 95% CI: 1.07, adjusted 
B-value 1.45, P < .01 for the less obesogenic antipsychotic group 
vs the nonpsychiatric control group and adjusted B-value 0.94, 
95% CI: 0.78, adjusted B-value 1.10, P < .01 for the clozapine group 
vs nonpsychiatric control group).
Correlation between Metabolic Parameters and 
Plasma Orexin-A Levels
In all the participants, plasma orexin-A levels were positively 
correlated with WC (r = 0.17, P < .05) and TG levels (r = 0.15, P < .05). 
Regarding the correlation between the orexin-A levels and meta-
bolic parameters in each group, the orexin-A levels were posi-
tively correlated with HDL-C (r = 0.26, P < .01) and HbA1C (r = 0.28, 
P < .05) levels, but negatively correlated with systolic BP (r = −0.28, 
P < .01) in the clozapine group and with FPG (r = −0.31, P < .05) in 
the less obesogenic antipsychotic group. The orexin-A levels and 
metabolic parameters were not correlated in the nonpsychiatric 
control group (Supplementary Table 1).
Logistic Regression Analysis for MS Explanatory 
Variables
First, we conducted univariate analyses by using logistic regres-
sion to investigate the potential explanatory variables of MS in 
the sample by using age, sex, smoking history, type of antipsy-
chotics (i.e., nonpsychiatric controls, patients taking less obeso-
genic antipsychotics, and clozapine) and orexin-A in tertiles as 
covariates (Table 2). The univariate analysis showed that older 
age, male sex, smoking, and treatment of clozapine were signifi-
cantly associated with MS. Second, in the multivariate analysis 
in model 1, the clozapine group was significantly associated 
with MS risk (adjusted OR = 5.10, 95% CI: 1.96–13.25, P < .01), with 
the nonpsychiatric controls as the reference group. Finally, 
by adding plasma orexin-A levels to the multivariate analysis 
in model 2, we observed that less obesogenic antipsychot-
ics (adjusted OR = 56.08, 95% CI: 5.22–602.67, P < .01), clozapine 
(adjusted OR = 82.15, 95% CI: 8.82–765.07, P < .01), and orexin-A 
levels (adjusted OR = 0.05, 95% CI: 0.01–0.39 for the 2nd tertile and 
Figure 1. Consort diagram with flow chart for patient inclusion in the study.
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adjusted OR = 0.04, 95% CI: 0.01–0.36 for the 3rd tertile, with both 
values P < .01) were associated with MS risk, after adjustment for 
age, sex, and smoking history. Higher orexin-A levels were sig-
nificantly associated with a lower risk of MS, even when the type 
of antipsychotics was considered a potential confounder.
Furthermore, because the orexin-A levels and metabolic 
parameters were not correlated in the nonpsychiatric controls, 
we examined the explanatory variables (namely age, sex, smok-
ing history, types of antipsychotics, duration of antipsychotic 
treatment, and BPRS scores) for MS only in the patient groups 
(Table 3). In the univariate model, only older age and male sex 
were significantly associated with MS, whereas the orexin-
A levels were inversely associated with MS. Smoking history, 
duration of antipsychotic treatment, type of antipsychotics, or 
BPRS scores was not associated with MS risk. In the multivariate 
model, orexin-A level was a predictive variable of MS (adjusted 
OR = 0.04, 95% CI: 0.01–0.38 for the 2nd tertile and adjusted 
OR = 0.04, 95% CI 0.01–0.36 for the 3rd tertile, both values P < .01), 
after adjustment for age, sex, smoking history, BPRS, types and 
duration of antipsychotic treatment.
Discussion
By dividing patients with schizophrenia into 2 groups according 
to the weight gain liability of their administered antipsychotics 
Table  1. Demographic and Metabolic Profiles of Patients Taking Clozapine, Less Obesogenic Antipsychotics, and Nonpsychiatric Controls 
(n = 219)
N (%) / Mean ± SD
P valuea Posthoc testcVariables
Clozapine
(n = 109)
Less obesogenic APs
(n = 50)
Nonpsychiatric controls
(n = 60)
Age (years) 41.97 ± 9.26 39.28 ± 9.15 41.10 ± 9.65 .24
Gender (male) 61 (56.0) 16 (32.0) 29 (48.3) .02
Antipsychotics treatment 
duration (years)
19.03 ± 9.56 14.94 ± 9.32 – .01
BPRS scores 26.47 ± 5.95 24.26 ± 5.34 – .04
Cigarette smoking 25 (23.8) 8 (16.7) 7 (11.7) .14
Metabolic profile
 MS 39 (35.8) 10 (20.0) 6 (10.0) <.01
 DM 17 (15.6) 2 (4.0) 4 (6.7) .05b
 IR 48 (44.0) 22 (44.0) 15 (25.0) <.05
 Hypertension 33 (30.8) 12 (24.0) 5 (8.3) <.01b
 Body weight (kg) 67.68 ± 13.04 67.07 ± 13.94 65.66 ± 18.44 .71d
 BMI (kg/m2) 25.05 ± 4.29 25.14 ± 4.97 24.00 ± 6.11 .37d
 Waist (cm) 87.29 ± 11.41 85.25 ± 12.72 79.31 ± 14.28 <.01d 1 > 3*, 2 > 3***
 Systolic BP (mmHg) 120.28 ± 14.94 118.50 ± 18.08 114.71 ± 16.27 .10d
 Diastolic BP (mmHg) 77.53 ± 11.66 73.20 ± 13.12 72.34 ± 10.00 .01d 1 > 3**
 Fasting glucose (mg/dL) 104.78 ± 16.36 92.48 ± 10.50 94.70 ± 23.23 <.01d 1 > 2***, 1 > 3***
 HbA1c (%) 5.68 ± 0.46 5.61 ± 0.42 – .39d –
 Triglyceride (mg/dL) 146.86 ± 95.60 130.20 ± 79.29 92.88 ± 56.78 <.01d 1 > 3*, 2 > 3***
 HDL-C (mg/dL) 48.33 ± 14.22 53.63 ± 15.82 59.07 ± 16.61 <.01d 3 > 1***
 Total cholesterol (mg/dL) 180.22 ± 38.00 183.08 ± 43.27 187.45 ± 35.63 .51d
 Insulin (uIU/mL) 10.17 ± 6.58 10.54 ± 6.84 9.88 ± 9.97 .90d
 HOMA-IR (mmol/L) 2.64 ± 1.80 2.45 ± 1.64 2.63 ± 3.69 .89d
Orexin-A (ng/mL) 1.54 ± 0.60 1.89 ± 0.50 0.60 ± 0.17 <.01d 2 > 1***, 2 > 3***, 1 > 3***
Abbreviations: BMI, body mass index; BP, blood pressure; BPRS, Brief Psychiatric Rating Scale-18; DM, debates mellitus type 2; HbA1c,glycated 
hemoglobin; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment for insulin resistance; IR, insulin resist-
ance; MS, metabolic syndrome.
a P values of 1-way ANOVA tests / independent t tests for continuous variables or chi-square tests for categorical variables.
b P value for Fisher’s exact test.
c 1 = patients taking clozapine; 2 = patients taking less obesogenic antipsychotics; 3 = nonpsychiatric controls. *P < .05, **P < .01, *** P < 01 for P value for posthoc tests.
d The data have been logarithmic transformed before proceeding with the statistical analyses.
Figure 2. Box plot of plasma orexin-A levels (ng/mL) in patients taking different 
antipsychotics and nonpsychiatric controls with comparisons by Welch’s 1-way 
ANOVA (posthoc multiple tests by the Games-Howell methods). The box plot 
whiskers indicate the highest, median, and lowest plasma orexin-A values that 
are no greater than 1.5 times the interquartile range, whereas the open circles 
are outlier values.
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(Lieberman et al., 2005; Leucht et al., 2013; Vancampfort et al., 
2015) rather than by first- or second-generation antipsychotics, 
we found, consistent with the literature (Kang and Lee, 2015), 
that the patients taking clozapine had more unfavorable plasma 
lipid and glucose parameters than the patients taking less obe-
sogenic antipsychotics. Furthermore, patients with schizophre-
nia had significantly higher levels of orexin-A compared with 
nonpsychiatric controls. Among the patients, individuals tak-
ing less obesogenic antipsychotics had higher orexin-A levels 
than those taking clozapine. This is the first study to show a sig-
nificant correlation between orexin-A levels and various meta-
bolic parameters in patients receiving long-term antipsychotic 
treatment. We propose that antipsychotics modify the effects 
of orexin-A on metabolic parameters and that higher orexin-A 
levels are associated with a lower risk of MS in patients with 
schizophrenia. These results highlight the potential protect-
ive role of orexin-A against the development of antipsychotic-
related metabolic abnormalities.
Table 3. Univariate and Multivariate Analyses of Risk Factors on Metabolic Syndrome in Patients with Schizophrenia by Logistic Regression 
(n = 157)
Explanatory variables
N (%)
Unadjusted OR (95% CI) Adjusted OR (95% CI)MS (n = 49) Non-MS (n = 108)
Age in years 1.04 (1.01–1.08)* 1.03 (0.98–1.09)
Gender
 Female 18 (36.7) 62 (57.4) Ref – Ref –
 Male 31 (63.3) 46 (42.6) 2.32 (1.16–4.65)* 1.45 (0.60–3.48)
Cigarette smoking
 No 34 (69.4) 85 (78.7) Ref – Ref –
 Yes 14 (28.6) 18 (16.7) 1.94 (0.87–4.34) 1.82 (0.69–4.80)
 Missing 1 (2.0) 5 (4.6) 0.50 (0.06–4.44) 0.06 (0.01–1.51)
Type of antipsychotics
 Less obesogenic APs 10 (20.4) 39 (36.1) Ref – Ref –
 Clozapine 39 (79.6) 69 (63.9) 2.20 (0.99–4.90) 1.55 (0.62–3.87)
BPRS scores 0.99 (0.93–1.06) 0.99 (0.92–1.06)
APs treatment duration in years 1.03 (0.99–1.07) 1.00 (0.95–1.05)
Orexin-A
 1st tertile (0.33–0.93) 10 (20.4) 2 (1.9) Ref – Ref –
 2nd tertile (0.94–1.59) 21 (42.9) 51 (47.2) 0.08 (0.02, 0.41)** 0.04 (0.01, 0.38)**
 3rd tertile (1.60–3.18) 18 (36.7) 55 (50.9) 0.07 (0.01, 0.33)** 0.04 (0.01, 0.36)**
Abbreviations: Aps, antipsychotics; BPRS, Brief Psychiatric Rating Scale-18; MS, metabolic syndrome; OR odds ratio.
*P < .05, **P < .01.
Table 2. Univariate and Multivariate Analyses of Risk Factors on Metabolic Syndrome in All Participants (Including Patients with Schizophrenia 
and Nonpsychiatric Participants) by Logistic Regression (n = 217)
Explanatory Variables
N (%)
Unadjusted OR (95% 
CI)
Adjusted OR (95% CI)
MS (n = 55) Non-MS (n = 162) Model 1a Model 2b
Age in years 1.04 (1.01–1.07)* 1.03 (0.99–1.07) 1.03 (0.99–1.07)
Gender
 Female 19 (34.5) 92 (56.8) Ref – Ref – Ref –
 Male 36 (65.5) 70 (43.2) 2.49 (1.32–4.71)** 2.08 (1.01–4.32)* 1.77 (0.81–3.87)
Cigarette smoking
 No 39 (70.9) 133 (82.1) Ref – Ref – Ref –
 Yes 15 (27.3) 24 (14.8) 2.13 (1.02–4.46)* 1.22 (0.52–2.84) 1.57 (0.65–3.79)
 Missing 1 (1.82) 5 (3.1) 0.68 (0.08–6.01) 0.36 (0.04–3.55) 0.06 (0.01–1.41)
Type of antipsychotics
 Nonpsychiatric controls 6 (10.9) 54 (32.9) Ref – Ref – Ref –
 Less obesogenic APs 10 (18.2) 39 (24.1) 2.31 (0.77–6.88) 2.87 (0.93–8.88) 56.08 (5.22–602.67)**
 Clozapine 39 (70.9) 69 (42.6) 5.09 (2.01–12.90)** 5.10 (1.96–13.25)** 82.15 (8.82–765.07)**
Orexin-Ac
 1st tertile (0.33–0.93) 16 (29.09) 52 (32.10) Ref – Ref –
 2nd tertile (0.94–1.59) 21 (38.18) 55 (33.95) 1.24 (0.58, 2.63) 0.05 (0.01, 0.39)**
 3rd tertile (1.60–3.18) 18 (32.73) 55 (33.95) 1.06 (0.49, 2.30) 0.04 (0.01, 0.36)**
Abbreviations: Aps, antipsychotics; MS, metabolic syndrome; OR, odds ratio.
aModel 1: covariates including age, gender, cigarrete smoking, and participant groups (nonpsychiatric controls, patients taking less obesogenic antipsychotics or 
patients taking clozapine group).
bModel 2: covariates including age, gender, cigarrete smoking, participant groups (nonpsychiatric controls, patients taking less obesogenic antipsychotics or patients 
taking clozapine), and orexin-A in tertiles.
c The data have been logarithmic transformed before proceeding with the statistical analyses.
*P < .05, **P < .01.
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Our observation of increased orexin-A levels in patients with 
schizophrenia receiving antipsychotic treatment is in agreement 
with a recent report by Chien et al. (Chien et al., 2015). They also 
showed that long-term antipsychotic treatment is associated 
with relatively high levels of orexin-A, although a specific antip-
sychotic-type difference was not found. Evidence of orexin-A 
changes (an increase or decrease) is inconclusive. For example, 
Dalal et al. reported that the CSF orexin-A levels in patients fol-
lowing treatment with haloperidol for 1 to 8 weeks (n = 7) were 
lower than that in unmedicated patients (n = 12), but the levels 
in patients treated with clozapine or olanzapine (n = 8) did not 
differ from that in the unmedicated patients (Dalal et al., 2003). 
Basoglu et al. also demonstrated a decrease in plasma orexin-
A levels following 6 weeks of olanzapine treatment in patients 
with first-episode schizophrenia (n = 20) compared with controls 
(n = 22) (Basoglu et al., 2010). These mixed results may be due to 
the sample characteristics, including sample size and duration 
of antipsychotic treatment, as well as different antipsychotic 
medications that were used across studies. Patients in our study 
had a longer treatment period (17.8 ± 9.6  years, ranging from 
6 months to 40 years) compared with relatively shorter periods 
(1–6 weeks) for those enrolled in previous studies. Moreover, our 
sample size was larger, especially the clozapine-administered 
group, which enabled us to divide the patients by the weight 
gain liability of the antipsychotics they were taking, and, thus, to 
present more homogenous groups (Chien et al., 2015). Therefore, 
our findings may reflect the adaptive responses of the orexin 
system to long-term antipsychotic exposure. Nevertheless, how 
the treatment affects orexin-A expression should be further 
examined in longitudinal follow-up studies.
The literature on the correlation between orexin-A levels 
and metabolic parameters in nonpsychiatric controls is also 
contradictory. Although some studies have reported reduced 
levels of orexin-A in individuals with morbid obesity compared 
with individuals with normal weight (Baranowska et al., 2005) 
and a negative correlation with BMI (Adam et al., 2002), other 
studies have found that the orexin-A levels in individuals with 
MS (Tabak et al., 2012) or morbid obesity were increased, with a 
potentially positive correlation between orexin-A levels and BMI 
(Heinonen et  al., 2005; Cigdem Arica et  al., 2013). Researchers 
have suggested that these conflicting results are due to com-
plex compensatory changes of orexin during the progression of 
metabolic abnormalities (Adam et al., 2002; Baranowska et al., 
2005; Heinonen et al., 2005; Tabak et al., 2012; Cigdem Arica et al., 
2013). In our nonpsychiatric controls, no correlation was found 
between orexin-A levels and BMI or other metabolic parameters. 
We speculate that the relatively few participants with morbid 
obesity (n = 7) and MS (n = 6) in our control group might have con-
tributed to the lack of correlation.
Accumulating evidence suggests that the orexin neuron sys-
tem plays a governing role in regulating eating behavior, meta-
bolic function, and energy expenditure by integrating central 
and peripheral signals in a complex manner (Tsuneki et  al., 
2010). Preclinical studies have reported that orexin-A promotes 
feeding behavior (Sakurai et al., 1998), whereas ablation of the 
orexin neurons suppresses this behavior (Inutsuka et al., 2014). 
The orexin neuron system can also prevent the development 
of obesity, reduce adiposity by stimulating thermogenesis and 
energy expenditure through increasing sympathetic nerve activ-
ity (Messina et al., 2018), and reduce peripheral insulin resist-
ance (Tsuneki et al., 2015). Peripheral orexin-A may exert its own 
direct metabolic effects while simultaneously interacting with 
the central orexin system and acting synergistically to affect 
metabolism. Furthermore, exogenous orexin-A administration 
has been shown to be beneficial in certain metabolic functions, 
including reducing blood glucose levels after a glucose load 
by enhancing the insulin secretion and reducing plasma glu-
cagon in both normal and diabetic mice (Park et  al., 2015). In 
line with the notion that orexin-A might oppose metabolic dis-
turbances, our clinical observation that orexin-A is associated 
with a relatively low risk of MS also suggests that an increase in 
orexin-A counteracts the adverse metabolic outcomes related to 
chronic antipsychotic treatment. The protective effect of orexin-
A may be attributable to an increase in the sympathetic tone 
and thermogenesis (Tsuneki et  al., 2015; Messina et  al., 2017). 
Studies have shown that a single dose of various antipsychotic 
treatments suppressed the sympathetic activation and thermo-
genesis effect that was induced by a central orexin-A injection 
(Monda et  al., 2003, 2004, 2008, 2018). An extended exposure 
of antipsychotics may cause a compensatory upregulation of 
orexin-A to restore the sympathetic balance.
The lower levels of orexin-A in the clozapine group compared 
with the less obesogenic group might reflect a reduced ability to 
upregulate orexin-A, thereby causing a higher susceptibility to 
weight gain. Moreover, studies have shown that the suppression 
effect of antipsychotics on orexin-A-induced sympathetic acti-
vation varies across different drugs: haloperidol exhibited a par-
tial suppression effect (Monda et al., 2003), whereas clozapine 
(Monda et  al., 2004) and olanzapine (Monda et  al., 2008) com-
pletely blocked sympathetic activation. Orexin neurons are reg-
ulated by serotoninergic, dopaminergic, and adrenergic neurons 
(Yamanaka et al., 2006). Therefore, it is likely that antipsychotics 
with diverse neurotransmitter receptor affinity profiles affect 
the action of orexin neurons differently. The differential influ-
ence on the orexin system between different antipsychotics 
was observed by Fadel et al., who reported that acute treatment 
of antipsychotics with higher weight gain liabilities induced 
immediate-early gene c-Fos expression in orexin neurons, but 
such induction was not seen in antipsychotics with a lower 
weight gain liability (Fadel et  al., 2002). Although this obser-
vation may appear to be in contrast with our findings, which 
instead reported decreased orexin levels in patients receiving 
clozapine, it is probable that the compensatory response of the 
orexin system following long-term antipsychotic treatment 
is distinct from an acute effect. Nevertheless, additional stud-
ies are required to investigate whether antipsychotic-induced 
suppression on the sympathetic effect of orexin-A directly con-
tributes to the metabolic adversities associated with long-term 
antipsychotic treatment.
Our study has several limitations. Because of the small sam-
ple size, we pooled patients under aripiprazole, haloperidol, 
amisulpride, and ziprasidone treatment into 1 group, less obeso-
genic antipsychotics, even though each antipsychotic has a dis-
tinct neurotransmitter profile and metabolic adversity liability. 
Although no difference was detected in the metabolic profiles of 
the participants, in MS prevalence, or in the plasma orexin-A levels 
in patients taking different types of antipsychotics with less obe-
sogenic liability (data not shown), the number of participants for 
each antipsychotic agent in this group was small, which did not 
allow us to detect differences among them. Second, we included a 
nonpsychiatric control rather than drug-naïve patients. Although 
a previous study reported no difference in CSF orexin-A levels 
between patients with schizophrenic disorder and normal controls 
(Nishino et al., 2002), we cannot exclude the effect of schizophre-
nia per se on orexin-A levels. Third, our patients displayed hetero-
geneity in their clinical profiles (i.e., those taking clozapine showed 
higher psychotic severity, and a greater proportion of those taking 
less obesogenic antipsychotics were women). However, by using 
the multivariate model, we found that the effect of the severity of 
psychotic symptoms or the sex distribution on the association of 
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orexin-A levels with risk of MS was not significant. Fourth, we did 
not have information regarding the type of antipsychotic treatment 
administered 6 months prior to enrollment as well as diet and level 
of physical activity; thus, we cannot eliminate a long-lasting meta-
bolic influence from previous antipsychotic treatments or from diet 
or exercise variance. Fifth, the causality in the association between 
orexin-A and metabolic measurements could not be examined in 
this cross-sectional study. Further prospective longitudinal studies 
measuring orexin levels during antipsychotic treatment may help 
to clarify this. Finally, orexin-A concentrations in previous stud-
ies using radioimmunoassay or EIA methods distributed in a con-
siderably wide range from a mean of 2430 ng/mL to a median of 
0.00065 ng/mL (Cintron et al., 2017). Although the orexin-A levels 
in our study (mean = 1.36 ng/mL, SD = 0.70, ranging from 0.33 ng/mL 
to 3.18 ng/mL) were of a similar range to previous studies using EIA 
methods (Sanchez-de-la-Torre et al., 2011; Chen et al., 2016; Cintron 
et al., 2017), both radioimmunoassay and EIA methods are subject-
ive to different antibodies, radioligands, reagents, and other experi-
mental conditions and thus can only produce “relative” instead of 
absolute measurements, precluding us from a direct comparison of 
the values across studies (Nishino, 2005).
In conclusion, our study suggests that long-term antipsychotic 
treatment is associated with increased levels of orexin-A. Patients 
treated with clozapine had lower orexin-A levels than those treated 
with less obesogenic agents. Higher plasma orexin-A levels were asso-
ciated with favorable lipid and BP profiles in the antipsychotic-treated 
patients. Additionally, higher orexin-A levels were associated with a 
lower risk of MS development. In summary, our study supports the role 
of the orexin system in the regulation of antipsychotic-related meta-
bolic abnormalities. Moreover, upregulation of orexin-A potentially 
exerts a protective effect. Additional studies are required to examine 
the causal relationship between adaptive responses of orexin-A levels 
and metabolic dysregulation as well as to investigate whether enhanc-
ing the orexin-A system would be advantageous in patients with 
schizophrenia who display or carry a risk of developing MS.
Supplementary Materials
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